International Clinical Trial: Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo(R) in combination with Yervoy(R)

Geneva, June 4 -- International Clinical Trials Registry received information related to the study (CTIS2023-507865-24-00) titled 'Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo(R) in combination with Yervoy(R)' on March 25, 2024.

Study Type: Interventional clinical trial of medicinal product

Study Design: Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Number of treatment arms in the trial:

Primary Sponsor: H e x a l AG

Condition: Advanced (unresectable/metastatic) melanoma MedDRA version: 21.1Lev...